Sortilin-related receptor is a druggable therapeutic target in breast cancer
H. Al-Akhrass, M. Pietilä, J. Lilja, E.-M. Vesilahti, J. M. Anttila, H. M. Haikala, P. M. Munne, J. Klefström, E. Peuhu, J. Ivaska
This study shows that targeting SorLA with a monoclonal antibody can overcome HER2 resistance in breast cancer, both in vitro and in vivo.
bioRxiv · Mar 9, 2021Cancer Biology